Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$4.96 +0.37%

+$0.03 today

Market cap
$194.19M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.43M

Average 0.36M

Returns on capital

Entrada Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-47.0%

avg -0.3%

ROIC

-43.7%

avg -32.9%

ROA

-38.1%

avg -24.0%

Analysis

ROA is currently the strongest return metric at -38.1% versus its period average of -24.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Dipal Doshi

Chief Executive Officer & DirectorUSD 998.25K50517.29K1.33%

Natarajan Sethuraman

President of Research & DevelopmentUSD 768K64214.24K0.55%

Nathan J. Dowden

President & Chief Operating OfficerUSD 737.18K55196.06K0.51%

Kerry Robert

Senior Vice President of People————

Jared Cohen

General Counsel————

Kevin Healy

Senior Vice President of Regulatory Affairs————

Kory James Wentworth

Chief Financial Officer & Treasurer—47117.28K0.30%

Karla MacDonald

Chief Corporate Affairs Officer————

Linea Aspesi

Chief People Officer—56——

Sandeep Basnet

Head of Information Technology————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

5

$291,162.12

Sells

42

$11.58M

Net Transaction Value

−$11.29M

Net selling

Most Active

MPM BIOVENTURES 2018, L.P.

12 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 9, 26

MPM BIOVENTURES 2018, L.P.

Indirect

Sell$205.6K
Sep 9, 26

MPM BioVentures 2014, L.P.

Indirect

Sell$205.6K
Sep 8, 26

MPM BIOVENTURES 2018, L.P.

Indirect

Sell$1.4M
Sep 8, 26

MPM BioVentures 2014, L.P.

Indirect

Sell$1.4M
Sep 4, 26

MPM BIOVENTURES 2018, L.P.

Indirect

Sell$273.7K
Sep 4, 26

MPM BioVentures 2014, L.P.

Indirect

Sell$273.7K
Sep 3, 26

MPM BIOVENTURES 2018, L.P.

Indirect

Sell$231.3K
Sep 3, 26

MPM BioVentures 2014, L.P.

Indirect

Sell$231.3K
Sep 2, 26

MPM BIOVENTURES 2018, L.P.

Indirect

Sell$180.7K
Sep 2, 26

MPM BioVentures 2014, L.P.

Indirect

Sell$180.7K

1–10 of 47

Summary

Insiders reported 5 buys worth $291,162.12 and 42 sells worth $11.58M over the last 12 months. That adds up to net selling of $11.29M. MPM BIOVENTURES 2018, L.P. was the most active insider with 12 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+38.0% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Forward estimates point to Revenue at +38.0% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Entrada Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about TRDA's management, answered from reported figures.

Who manages TRDA?

Entrada Therapeutics, Inc. (TRDA) lists 10 active executives. The top listed executive is Kerry Robert, Senior Vice President of People.

Are TRDA insiders buying or selling?

Recent insider activity shows net selling of $7.66M.